World Expert on Angiotensin I-Converting Enzyme Joins GenoMed's Scientific Advisory Board
ST. LOUIS, Dec. 12 /PRNewswire-FirstCall/ -- GenoMed, Inc. (OTC Pink Sheets: GMED) ("the Company" or "GenoMed"), a St. Louis, Missouri-based medical genomics company, announced today that Sergei Danilov, M.D., Ph.D., Dr.Sci. has joined its Scientific Advisory Board.
Dr. Danilov is one of the half-dozen or so world experts on the angiotensin I-converting enzyme (ACE). Between 1986 and 1993, while Deputy Director of the Cell Biology Department of the National Cardiology Research Center in Moscow, Russia, he developed over a dozen monoclonal antibodies against ACE. He used these antibodies to probe the role of ACE in normal physiology and disease. Dr. Danilov is the author of over 80 journal articles, of which 56 relate to ACE.
Dr. David Moskowitz, GenoMed's Chairman, said, "We are honored to have Dr. Danilov agree to join our Scientific Advisory Board. He is a biochemist and cell biologist who has contributed as much as anyone to understanding the role that ACE plays in the body, as well as the diagnostic and therapeutic potential of monoclonal antibodies to this clinically relevant enzyme. Now that we are signing up patients for our novel treatment approach, we need to have a way to follow them clinically. Dr. Danilov has agreed to help us develop a diagnostic test to follow how completely we are blocking tissue ACE in individual patients."
Dr. Danilov is the author of six Russian patents and one American patent. He is a world expert in measuring the activity of the ACE enzyme in blood and tissues. He has agreed to work with GenoMed on the development of a tissue ACE assay for use in following patients clinically, for which GenoMed has patents pending.
Dr. Danilov said, "It is a delight to have spent my entire professional life working on ACE and to finally have it mean a lot to patients. I am very excited to be working with GenoMed on this project."
About GenoMed
GenoMed, Inc. is a medical genomics company whose mission is to improve patient outcomes by identifying the genes that cause disease. A recent St. Louis Business Journal article (http://www.stlouis.bizjournals.com/stlouis/stories/2002/05/13/story8.html) reported that the company has applied for patents based on its finding that the ACE gene is associated with over 100 common, age-related diseases. The Company has filed patent applications on its new treatments for both human and veterinary use.
For questions, please contact Krissy Fischer, tel. 1-877-GENOMED (1-877-436-6633), FAX 314-977-0042, email: kfischer@genomedics.com, or visit GenoMed at www.genomedics.com.
SOURCE GenoMed, Inc.
CONTACT: Krissy Fischer of GenoMed, Inc., +1-877-GENOMED, or
+1-877-436-6633, or fax, +1-314-977-0042, or kfischer@genomedics.com/
Web site: genomedics.com
. |
